NASDAQ:VKTX Viking Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.77 +0.06 (+2.21%) (As of 06/29/2022 04:00 PM ET) Add Compare Share Today's Range$2.59▼$2.7950-Day Range$2.11▼$2.8852-Week Range$2.02▼$7.20Volume760,053 shsAverage Volume1.12 million shsMarket Capitalization$214.33 millionP/E RatioN/ADividend YieldN/APrice Target$13.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VKTX Stock Forecast (MarketRank)Overall MarketRank™1.87 out of 5 starsMedical Sector723rd out of 1,432 stocksPharmaceutical Preparations Industry349th out of 685 stocksAnalyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingViking Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.50, Viking Therapeutics has a forecasted upside of 387.4% from its current price of $2.77.Amount of Analyst CoverageViking Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Community Rank Outperform VotesViking Therapeutics has received 570 “outperform” votes. (Add your “outperform” vote.)Underperform VotesViking Therapeutics has received 124 “underperform” votes. (Add your “underperform” vote.)Community SentimentViking Therapeutics has received 82.13% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote “Outperform” if you believe VKTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VKTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldViking Therapeutics does not currently pay a dividend.Dividend GrowthViking Therapeutics does not have a long track record of dividend growth. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Viking Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Viking Therapeutics is held by insiders.Percentage Held by Institutions46.74% of the stock of Viking Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Viking Therapeutics are expected to decrease in the coming year, from ($0.90) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viking Therapeutics is -3.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viking Therapeutics is -3.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViking Therapeutics has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Viking Therapeutics (NASDAQ:VKTX)Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.Read More VKTX Stock News HeadlinesJune 7, 2022 | finance.yahoo.comIntercept (ICPT) Announces Delay in Meeting With the FDAJune 6, 2022 | finance.yahoo.comOne Viking Therapeutics, Inc. (NASDAQ:VKTX) insider upped their stake by 43% in the previous yearMay 16, 2022 | finance.yahoo.comViking Therapeutics to Present at H.C. Wainwright Global Investment ConferenceApril 28, 2022 | benzinga.comSVB Leerink Maintains Outperform on Viking Therapeutics, Lowers Price Target to $12April 28, 2022 | seekingalpha.comViking Therapeutics' (VKTX) CEO Brian Lian on Q1 2022 Results - Earnings CallApril 27, 2022 | za.investing.comViking Therapeutics Misses Q1 EPS by 2cApril 27, 2022 | seekingalpha.comViking Therapeutics GAAP EPS of -$0.21 misses by $0.02April 27, 2022 | finance.yahoo.comViking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate UpdateApril 20, 2022 | seekingalpha.comRevisiting Viking TherapeuticsApril 6, 2022 | finance.yahoo.comViking Therapeutics to Present at the 21st Annual Needham Virtual Healthcare ConferenceMarch 8, 2022 | finance.yahoo.comViking Therapeutics to Present at Upcoming Investor ConferencesFebruary 10, 2022 | seekingalpha.comViking Therapeutics rises 8% following Q4 resultsFebruary 7, 2022 | finance.yahoo.comViking Therapeutics to Present at SVB Leerink 11th Annual Global Healthcare ConferenceSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VKTX CUSIPN/A CIK1607678 Webwww.vikingtherapeutics.com Phone(858) 704-4660FaxN/AEmployees17Year FoundedN/ACompany Calendar Last Earnings4/27/2022Today6/29/2022Next Earnings (Estimated)7/27/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$13.50 High Stock Price Forecast$15.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+387.4%Consensus RatingBuy Rating Score (0-4)3 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.740010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54.99 million Net MarginsN/A Pretax MarginN/A Return on Equity-27.77% Return on Assets-26.31% Debt Debt-to-Equity RatioN/A Current Ratio17.16 Quick Ratio17.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.58 per share Price / Book1.07Miscellaneous Outstanding Shares77,374,000Free Float73,118,000Market Cap$214.33 million OptionableOptionable Beta1.74 Viking Therapeutics Frequently Asked Questions Should I buy or sell Viking Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Viking Therapeutics stock. View analyst ratings for Viking Therapeutics or view top-rated stocks. What is Viking Therapeutics' stock price forecast for 2022? 5 Wall Street analysts have issued 1-year price objectives for Viking Therapeutics' shares. Their VKTX stock forecasts range from $10.00 to $15.00. On average, they predict Viking Therapeutics' stock price to reach $13.50 in the next twelve months. This suggests a possible upside of 387.4% from the stock's current price. View analysts' price targets for Viking Therapeutics or view top-rated stocks among Wall Street analysts. How has Viking Therapeutics' stock price performed in 2022? Viking Therapeutics' stock was trading at $4.60 at the beginning of the year. Since then, VKTX stock has decreased by 39.8% and is now trading at $2.77. View the best growth stocks for 2022 here. When is Viking Therapeutics' next earnings date? Viking Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022. View our earnings forecast for Viking Therapeutics. How were Viking Therapeutics' earnings last quarter? Viking Therapeutics, Inc. (NASDAQ:VKTX) released its quarterly earnings results on Wednesday, April, 27th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01. During the same period in the prior year, the business posted ($0.19) EPS. View Viking Therapeutics' earnings history. Who are Viking Therapeutics' key executives? Viking Therapeutics' management team includes the following people: Dr. Brian Lian Ph.D., Pres, CEO & Director (Age 56, Pay $872k)Mr. Gregory S. Zante, Chief Financial Officer (Age 51, Pay $536k)Ms. Marianne Mancini, Chief Operating Officer (Age 57, Pay $543k)Mr. Michael Morneau, VP of Fin. & Admin. (Age 57) Who are some of Viking Therapeutics' key competitors? Some companies that are related to Viking Therapeutics include ADVANZ PHARMA (CXRXF), Morphic (MORF), SIGA Technologies (SIGA), IGM Biosciences (IGMS), Design Therapeutics (DSGN), Phibro Animal Health (PAHC), Nuvation Bio (NUVB), Verve Therapeutics (VERV), Nektar Therapeutics (NKTR), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Avidity Biosciences (RNA), Belite Bio (BLTE), Kiniksa Pharmaceuticals (KNSA) and MorphoSys (MOR). View all of VKTX's competitors. What other stocks do shareholders of Viking Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO). When did Viking Therapeutics IPO? (VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager. What is Viking Therapeutics' stock symbol? Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX." How do I buy shares of Viking Therapeutics? Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Viking Therapeutics' stock price today? One share of VKTX stock can currently be purchased for approximately $2.77. How much money does Viking Therapeutics make? Viking Therapeutics (NASDAQ:VKTX) has a market capitalization of $214.33 million. The biotechnology company earns $-54.99 million in net income (profit) each year or ($0.740010) on an earnings per share basis. How many employees does Viking Therapeutics have? Viking Therapeutics employs 17 workers across the globe. How can I contact Viking Therapeutics? Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for Viking Therapeutics is www.vikingtherapeutics.com. The biotechnology company can be reached via phone at (858) 704-4660 or via email at [email protected]. This page (NASDAQ:VKTX) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
